Principal Scientist
Role
Enodia Therapeutics is looking for an experienced and scientifically rigorous Principal Scientist to provide recognized scientific expertise across our discovery and preclinical programs and shape scientific approaches to complex questions involving target biology, drug mechanisms and selective Sec61 inhibition.
The successful candidate will integrate multidisciplinary evidence, influence scientific direction and methodologies across projects, and guide experimental strategy for complex target biology and drug discovery questions.
Working across interdisciplinary project teams, the Principal Scientist will provide scientific leadership through expertise, critical thinking and evidence-based recommendations, while contributing to program-level decisions and the advancement of Enodia’s growing pipeline.
Main Responsibilities
- Lead the scientific strategy and cross-functional efforts to build a robust preclinical data package that successfully transitions candidates into clinical development.
- Provide recognized cross-project scientific expertise and influence scientific approaches, methodologies and complex problem-solving.
- Shape experimental strategy for complex target biology and drug discovery questions and guide the selection and integration of relevant models, assays and technologies.
- Integrate complex and multidisciplinary scientific data to generate hypotheses, challenge assumptions and guide program-level recommendations and next steps.
- Influence scientific direction across projects by connecting findings to target validation, mechanism of action, therapeutic potential and key project decision points.
- Provide scientific guidance, mentoring and constructive challenge to project teams and less experienced colleagues.
- Communicate complex scientific findings, recommendations, uncertainties and risks clearly to project, senior and relevant external audiences.
- Maintain broad scientific awareness and collaborate with external academic partners, KOLs and CROs where relevant.
Professional Experience / Qualifications
- PhD and/or postdoctoral experience in Immunology, Oncology, Tumor Immunology or another field relevant to Enodia’s programs.
- Extensive relevant research experience in biotech/pharma or a comparable academic environment specifically in building datasets in support of IND/CTA submissions.
- Recognized depth and/or breadth of scientific expertise relevant to target biology, drug discovery and preclinical research including preclinical models
- Demonstrated ability to integrate multiple experimental approaches and data types to address complex program-level scientific questions.
- Strong track record of scientific productivity and meaningful contribution to drug discovery or complex research programs.
- Demonstrated ability to influence scientific strategy and decision-making across projects through expertise, critical thinking and evidence-based recommendations.
- Strong scientific leadership, mentoring, communication and collaboration skills, without requiring formal people-management responsibility.
- Excellent command of English, strong autonomy, rigor, effective time management and adaptability.
Offer
- A stimulating position within a high-potential innovative biotech company.
- The opportunity to work in a science-driven, dynamic, respectful, and professional environment.
- A challenging scientific and business growth in which you get to bring your knowledge and skills.
- An employment agreement contract with an attractive salary package in line with the position responsibilities and your experience.
Recruitment Process
Please send your CV together with an adapted cover letter using the application form below.
Your application and related information will remain strictly confidential.
For this open position in Belgium (Liège), we closely collaborate with Parhtners (Recruitment & Selection company). Your application will be automatically forwarded to them. We, together with Parhtners, will keep all your data confidential (GDPR compliant approach).
About Enodia Therapeutics
Enodia Therapeutics is a French biotechnology company developing best-in-class small-molecule therapeutics based on a novel approach to controlling the production of disease-driving proteins at their source. Founded in 2025 from pioneering research conducted at Institut Pasteur and built with the support of the Argobio venture studio, Enodia brings together expertise in cutting-edge biology, medicinal chemistry, proteomics, structural biology, and artificial intelligence. The company operates across Paris, France, and Liège, Belgium.
At the heart of Enodia’s technology is the selective modulation of Sec61, a central gateway in the biogenesis of secreted and membrane proteins. By exploiting differences in the sensitivity of individual proteins to Sec61 modulation, we aim to selectively control defined sets of disease-relevant proteins while preserving essential cellular functions. This distinctive approach opens new opportunities to address disease-relevant proteins and mechanisms that remain challenging to target with conventional therapeutic strategies.
Enodia is advancing a growing preclinical pipeline across inflammation, immunology, and oncology, with additional opportunities in virology.
In early 2026, Enodia secured €20.7 million in Seed financing, co-led by Elaia, Pfizer Ventures, and Bpifrance, alongside leading French and international investors. This strong financial foundation enables us to advance our pipeline, expand our scientific capabilities, and build the team needed to bring our technology to the next stage of development.
Enodia is now entering an exciting phase of growth, with expanding teams in Paris and Liège. We offer the opportunity to work at the interface of cutting-edge science and drug discovery, collaborate closely across disciplines, and play a meaningful role in shaping both the development of a new therapeutic approach and the future of a growing biotech.